Insider Trading March 5, 2026

Alignment Healthcare CHRO Disposes $393K in Shares Under 10b5-1 Plan

Andreas Wagner sold 21,118 shares; company moves ahead with secondary offering while reporting robust Q4 growth

By Sofia Navarro ALHC
Alignment Healthcare CHRO Disposes $393K in Shares Under 10b5-1 Plan
ALHC

Alignment Healthcare Chief Human Resources Officer Andreas P. Wagner sold 21,118 shares of the company's common stock on March 4, 2026, generating roughly $393,250. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted Nov. 21, 2025. The company additionally disclosed a secondary offering led by an affiliate of General Atlantic, and reported strong fourth-quarter metrics including membership and revenue gains.

Key Points

  • Alignment Healthcare CHRO Andreas P. Wagner sold 21,118 shares on March 4, 2026, netting about $393,250 at a weighted-average price of $18.6216.
  • The company has priced a secondary offering of 13.2 million shares at $19.46 per share led by an affiliate of General Atlantic; Alignment Healthcare will not receive the offering proceeds.
  • Fourth-quarter results showed approximately 25% year-over-year membership growth and roughly 44.4% revenue growth, with a medical benefit ratio of 87.7% and SG&A ratio improving by about 115 basis points to 9.7%.

Transaction details

Alignment Healthcare (NASDAQ:ALHC) announced that Chief Human Resources Officer Andreas P. Wagner sold 21,118 shares of common stock on March 4, 2026, for approximately $393,250. The trade was executed at a weighted-average price of $18.6216, with individual sale prices spanning from $18.47 to $18.89.

Following the sale, Wagner directly holds 148,687 shares of Alignment Healthcare. The disposition was carried out through a pre-established Rule 10b5-1 trading plan that Wagner adopted on November 21, 2025.


Market context

The company's shares are currently trading at $18.88 and Alignment Healthcare has a market capitalization of $3.86 billion. The stock has fallen roughly 7.5% over the past week.

According to InvestingPro analysis, ALHC appears undervalued at current levels based on Fair Value metrics.


Secondary offering and related terms

Alignment Healthcare also disclosed that a secondary offering of 13.2 million shares has been priced at $19.46 per share. The offering is led by an affiliate of General Atlantic, L.P., and the company clarified that it will not receive any proceeds from the sale. The offering is expected to close on March 4, 2026, subject to customary closing conditions, with J.P. Morgan acting as the underwriter.


Quarterly results and analyst response

The company reported strong fourth-quarter performance, with membership increasing by approximately 25% year-over-year and revenues rising by approximately 44.4%. Management reported a medical benefit ratio of 87.7% and an improvement in the selling, general, and administrative expense ratio of about 115 basis points to 9.7%.

Following the quarterly results, Raymond James reiterated a Strong Buy rating with a $27.00 price target. Piper Sandler maintained an Overweight rating and set a $30.00 price target, both citing that Alignment Healthcare's fourth-quarter 2025 performance surpassed expectations.


What the filing and results show

The insider sale followed a pre-arranged trading plan and left Wagner with a meaningful personal stake in the company. At the same time, the company is navigating a sizeable secondary offering led by an affiliate investor while reporting outsized membership and revenue growth in the fourth quarter. Market reaction in the week prior to the filing showed a modest pullback in the share price.

Note: The information above reflects disclosure statements and company-reported results as provided in the filings and official announcements referenced.

Risks

  • Near-term share price volatility - the stock declined about 7.5% over the past week, which could affect market perception and trading liquidity.
  • Secondary offering execution risk - the offering is subject to customary closing conditions and the company will not receive proceeds, which may influence shareholder dynamics.
  • Concentration of operational metrics - the company’s financials include elevated medical benefit and expense ratios that investors may continue to scrutinize.

More from Insider Trading

Newmont Executive Disposes $164,381 in Stock Under 10b5-1 Plan Mar 5, 2026 Peoples Bancorp Director Sells 477 Shares; Holds Significant Direct and Indirect Stakes Mar 5, 2026 Newmont Executive Sells $164,381 in Stock as Firm Faces Mixed Analyst Views Mar 5, 2026 Peoples Bancorp Director Disposes of $17,935 in Stock; Company Declares Special Dividend Mar 5, 2026 Honest Company's Chief Innovation Officer Sells 73,685 Shares; Stock, Guidance and Analyst Takeaways Noted Mar 5, 2026